MARKET

LXRX

LXRX

Lexicon Pharmaceuticals Inc
NASDAQ
2.110
-0.050
-2.31%
After Hours: 2.090 -0.02 -0.95% 16:28 12/06 EST
OPEN
2.180
PREV CLOSE
2.160
HIGH
2.190
LOW
2.090
VOLUME
206.20K
TURNOVER
0
52 WEEK HIGH
4.719
52 WEEK LOW
1.310
MARKET CAP
398.21M
P/E (TTM)
-3.3631
1D
5D
1M
3M
1Y
5Y
Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference
THE WOODLANDS, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2022: 34th Annual Piper Sandler Healthcare C...
GlobeNewswire · 11/28 13:00
Lexicon's Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy Study
Benzinga · 11/15 15:00
BRIEF-Lexicon’S Lx9211 Shows Benefits In Treatment Of Diabetic Neuropathy In Results From The Phase 2 Relief-Dpn-1 Trial
Reuters · 11/14 21:49
Lexicon's LX9211 Shows Significant And Consistent Benefits In The Treatment Of Painful Diabetic Neuropathy In Full Results From The Phase 2 RELIEF-DPN-1 Trial Presented At The 16th Annual Pain Therapeutics Summit
Benzinga · 11/14 21:44
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
THE WOODLANDS, Texas, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13th Annual Jefferies London Healthcare Conference, taking place November 15-17, 2022. Jeff Wade, Lexicon’s presid...
GlobeNewswire · 11/11 13:58
Lexicon Pharmaceuticals Q3 EPS $(0.13) Beats $(0.14) Estimate, Sales $39.00K Miss $50.00K Estimate
Benzinga · 11/09 21:05
Lexicon Pharmaceuticals GAAP EPS of -$0.13
Seekingalpha · 11/09 21:03
BRIEF-Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results
Reuters · 11/09 21:02
More
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.

Webull offers kinds of Lexicon Pharmaceuticals Inc stock information, including NASDAQ:LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.